Sunday, July 5, 2026 See who Washington just made rich Go Pro · $40/mo →
Money Racket
Who Cashes In When Washington Moves
HEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Get a Bigger MarkettodayENERGYBWXT: The Naval Nuclear Contractor Riding a Civilian Policy Wave4 weeks agoDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Revenue Line for AeroVironmenttodayENERGYThe NRC Discount Helps Oklo More Than NuScale — Because NuScale Already Paid Full Price4 weeks agoWHITE HOUSEA US-Iran Ceasefire Deal Sends Oil Lower and Puts Defense Contractors on WatchtodayCRYPTOThe Anti-CBDC Play: No Digital Dollar Means Private Rails Win4 weeks agoHEALTHCARE & FDAFDA's BHT and ADA Reassessment Puts Food Additive Users on Notice — and Creates an Opening for Clean-Label SupplierstodayENERGYForget Which Reactor Wins — GE Vernova Owns the Queue4 weeks agoENERGYMissouri Joins Federal Nuclear Fast-Track Program, Adding Momentum to the SMR Buildout TradetodayCRYPTOThe Toll Booth at the Top of the Bitcoin ETF Stack4 weeks agoTRADE & TARIFFSNike's Tariff Refund Windfall Shows How Import-Heavy Brands Can Turn Trade Policy Into a Margin StorytodayCRYPTOThe IRS Closes the Crypto Wash-Sale Loophole — and Robinhood Collects the Toll4 weeks agoTECHTrump's Post-Quantum Cryptography Executive Order Creates a Compliance Spending Mandate — and Clear BeneficiariestodayENERGYCentrus vs. Cameco: Washington's Russian Uranium Ban Splits the Nuclear Fuel Chain4 weeks agoTRADE & TARIFFSNike's Tariff Refunds Are a One-Time Boost, Not a Structural Fix — Here's What the Q4 Beat Actually MeansyesterdayENERGYThe HALEU Contract Nobody Prices In4 weeks agoCRYPTOBitcoin Is Down 33% at Mid-Year and ETF Outflows Hit $4.3B in June — Coinbase and the Miners Are Feeling ItyesterdayCRYPTOThe Debanking Era Is Over. HOOD and Block Are Next in Line at the Window.4 weeks agoENERGYThe US-Iran Initial Deal Puts Sanction Relief on the Table — and That's a Headwind for Oil Prices and E&P StocksyesterdayENERGYWhy Constellation (CEG) Is Really a Policy Stock, Not a Utility Stock4 weeks agoENERGYWashington Is Rewriting Nuclear Radiation Safety Rules — Constellation, Vistra, and the SMR Crowd All WinyesterdayCRYPTOMining the Grid: How EPA and Energy Policy Set the Spread for Proof-of-Work Miners4 weeks agoDEFENSEHegseth's NATO Broadside and European Force Review Put Defense Primes in a Complicated SpotyesterdayCRYPTOThe Stablecoin Bill: Who Controls the On-Ramp When Congress Licenses It4 weeks agoTECHCommerce Department's AI Model Export Controls Are the Next Nvidia Headwind — and AMD Isn't ImmuneyesterdayENERGYWillow Isn't an Oil Play. It's an Interior Department Play.4 weeks agoHEALTHCARE & FDAMedicare Is Now Covering Wegovy — Novo Nordisk and Eli Lilly Just Got a Massive New PayeryesterdayCRYPTOBitcoin as Reserve Asset: The Federal Legitimacy Trade4 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Toddlers — Vertex and CRISPR Therapeutics Just Got a Bigger MarketyesterdayENERGYWho Gets Exposed When the SPR Refill Never Happens4 weeks agoWHITE HOUSETrump's Quantum Executive Order Sets a Hard Deadline — and Quantum Computing Stocks Are the Immediate BeneficiaryyesterdayENERGYWashington Fixed the LNG Permit. It Can't Fix a County Courthouse in Guilford County.4 weeks agoDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Payday for AeroVironment — and a Warning Shot for Its RivalsyesterdayENERGYThe Jones Act's Hidden LNG Winner: Foreign Tankers, Not U.S. Shippers, Cash In4 weeks agoWHITE HOUSETrump's Quantum Executive Orders Set a 2030 Deadline — and a Spending Clock for IonQ, Rigetti, and the Cybersecurity Stack2 days agoCRYPTOThe SEC Retreat: How a Friendlier Regulator Unlocks Coinbase's Business Model4 weeks agoDEFENSEHegseth's NATO Broadside and Europe Force Review Signal a Shift That Benefits U.S. Primes — at Europe's Expense2 days agoENERGYHalliburton vs. SLB: Who Actually Cashes In on Methane Compliance4 weeks agoHEALTHCARE & FDAMedicare Starts Covering GLP-1 Weight-Loss Drugs July 1 — Novo Nordisk and Eli Lilly Just Got 67 Million New Potential Customers2 days agoENERGYOccidental's Carbon Capture Isn't a Climate Bet. It's a Tax Credit Trade.3 weeks agoCRYPTOBitcoin ETF Outflows Hit $4.3 Billion in June — Coinbase, MARA, and Strategy Are Carrying the Most Risk2 days agoTECHThe Federal Data Center Mandate: How Washington's AI Spending Flows to Hardware3 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Just Got a Bigger Market2 days agoTECHThe Domestic Equipment Play: How Foreign Chip Tool Restrictions Hand Applied Materials a Structural Edge3 weeks agoDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Revenue Line for AeroVironment — and Pressure on Its Rivals2 days agoENERGYSLB's Quiet Second Act: How Sanctions Reroute the Oilfield Services Backlog3 weeks agoDEFENSEThe U.S.-Iran Ceasefire and $87.6B Pentagon Request Are Two Sides of the Same Defense Spending Boom3 days agoTECHThe AI Diffusion Rule Is Picking Winners Inside the Chip Stack — and It Is Not Who You Think3 weeks agoDEFENSELockheed's $35B Interceptor Contract Is the Biggest Missile-Defense Payday in Years — Here's Who Else Gets Paid3 days agoENERGYThe FERC Docket Nobody Reads: How Pipeline Certificates Quietly Pick LNG's Winners3 weeks agoWHITE HOUSETrump Suspends Fertilizer Tariffs — Farm Input Costs Drop and Ag Names Get a Quiet Tailwind3 days agoTECHThe HBM Monopoly: How Federal Memory Standards Lock In Micron3 weeks agoMARKETSThe Supreme Court Just Gave Trump Control Over the FTC — What That Means for M&A and Big Tech3 days agoTECHThe Tariff Arbitrage: How Chip Import Duties Reshape the Foundry Map3 weeks agoENERGYMissouri Joins Federal Nuclear Fast-Track and a U.S. Uranium Project Clears Permitting — The Nuclear Supply Chain Is Moving3 days agoENERGYWhy Williams (WMB) Is Really a Policy Stock, Not a Pipeline Stock3 weeks agoTRADE & TARIFFSTariff Refunds Are Flowing — Nike and FedEx Are Among the First to See Real Money3 days agoENERGYDOE Reopens the LNG Export Spigot: Cheniere Cashes In First, Kinder Morgan Collects the Toll3 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Just Got a Bigger Market3 days agoTECHThe Chip Stack Below the Pentagon's AI Buildup3 weeks agoDEFENSEThe F-35 Sustainment Lock-In: Why the Pentagon's Most Expensive Program Keeps Paying One Company Forever3 days agoDEFENSEHII's Mission Technologies: The Unsexy Segment Where Navy Autonomy Dollars Actually Land First3 weeks agoDEFENSEWhy L3Harris Is Really a Policy Stock, Not a Hardware Stock4 days agoTECHThe CHIPS Act Subsidy Ladder: Who Actually Receives the $39 Billion3 weeks agoTRADE & TARIFFSThe Tariff Refund Portal Is Open and Companies Are Cashing In — Nike and FedEx Are the Names to Watch4 days agoDEFENSEThe Refueling Line Nobody Prices Into BWXT3 weeks agoTRADE & TARIFFSTrump's Fertilizer Tariff Suspension Cuts Input Costs for Farmers — and Squeezes Domestic Producers4 days agoDEFENSEThe Law That Guarantees Matson a Buyer, No Matter the Price3 weeks agoMARKETSSupreme Court Gives Trump FTC Firing Power — Antitrust Enforcement Just Got More Political4 days agoENERGYThe Grid Hardening Bill Trade: How Federal Transmission Investment Lifts the Equipment Makers3 weeks agoDEFENSEThe Nuclear Triad Upgrade Cycle: Three Legs, Three Winners, Decades of Locked-In Spending4 days agoTECHThe Export Control Squeeze: BIS Chip Rules Are Splitting the AI Hardware Market in Two3 weeks agoDEFENSESentinel vs. Columbia: The Nuclear Triad's Budget Is a Zero-Sum Game4 days agoDEFENSEWho Loses if the Navy's 355-Ship Goal Quietly Becomes a 'Right-Sized Fleet' Retreat3 weeks agoDEFENSEThe FMS Loophole: How State Department Sign-Offs Insulate Defense Primes From Shutdown Risk5 days agoENERGYThe Only U.S. HALEU Cascade: How Centrus Became the Gatekeeper to the Advanced Reactor Boom3 weeks agoDEFENSEWhen the Pentagon Classifies a Budget Line: The Black Budget Trade5 days agoDEFENSEMatson and the Jones Act: The Shipping Monopoly Washington Refuses to Touch3 weeks agoDEFENSEHII Is a Congressional Appropriations Bet, Not a Navy Bet6 days agoDEFENSEThe Real Winner Behind the Navy's Shipbuilding "Get Well" Plan Is Second-Tier Suppliers, Not the Primes3 weeks agoDEFENSEWho Actually Cashes In on 'Golden Dome': The Subcontractor Layer Behind LMT and RTX6 days agoDEFENSELeidos: The Non-Obvious Beneficiary of Navy Digital and Sustainment Modernization3 weeks agoDEFENSENATO's 2% Mandate Is a Revenue Stream Disguised as an Alliance Obligation6 days agoENERGYThe Grid Reliability Mandate: FERC's Capacity Market Rules Are Writing Checks to Nuclear3 weeks agoDEFENSEThe Drone Proliferation Trade: Washington's Shift to Attritable Unmanned Systems Creates a Recurring Revenue Stream6 days agoENERGYThe Nuclear Restart Order: Only One Operator Has Actually Flipped the Switch3 weeks agoDEFENSEThe Loser Nobody Names: Export Controls Squeeze Boeing From Both Sideslast weekDEFENSEAUKUS Pillar I Is a Slow-Burn Catalyst for GD and HII, Not a Pop2 weeks agoDEFENSEThe Hypersonic Arms Race Has a Bottleneck — and Three Contractors Own Itlast weekENERGYWashington Plugs AI Into Reactors: The Behind-the-Meter Nuclear Offtake Trade2 weeks agoDEFENSESole-Source vs. Full-and-Open: The Slow Bleed in LMT's F-35 Sustainment Machinelast weekDEFENSEWhy BWXT Is Really a Policy Stock, Not an Industrial One2 weeks agoDEFENSELeidos Is the Quiet Beneficiary of Every "Modernize Federal IT" Executive Orderlast weekDEFENSEHII vs. General Dynamics: Who Wins the Submarine Industrial Base Money2 weeks agoDEFENSEThe Pentagon's AI Mandate: Why Defense Data Platforms Are Now a Weapons Programlast weekENERGYThe SMR Funding Funnel: How DOE's Loan Billions Flow to Small Modular Reactors2 weeks agoDEFENSEIron Dome and the FMS Pipeline: How Middle East Tensions Fund Missile Defense Primeslast weekENERGYThe Uranium Supply Squeeze: How the Russian Import Ban Flows to Cameco and Centrus2 weeks agoDEFENSEChina's Rare-Earth Squeeze Will Hit Defense Primes Unevenlylast weekDEFENSEPalantir's Real Moat Is the Data Rights Clause, Not the AI2 weeks agoENERGYThe SPR Refill Trade: Who Gets Paid When Washington Buys Oillast weekENERGYThe Nuclear Production Tax Credit Trade: Who Gets Paid to Keep Old Reactors Alive2 weeks agoDEFENSERTX's Two-Front Bet: Why Iran Tensions and NATO's 5% Pledge Hit the Same Ticker Differentlylast weekDEFENSEElbit's America Problem: What Buy American Rules Really Do to a Foreign Prime2 weeks agoENERGYLNG Export Licenses: How a FERC Approval Mints a Monopolylast weekDEFENSECounter-Drone Spending Is the Quiet Twin of Drone Spending2 weeks agoDEFENSEKratos vs. AeroVironment: Which One Actually Wins the Cheap-Drone-Swarm Pivotlast weekENERGYSanctions Relief and the LNG Arbitrage: When State Department Decisions Move the Henry Hub2 weeks agoDEFENSEMercury Systems: The Toll Booth Every Drone and Missile Program Has to Pass Throughlast weekDEFENSELeidos: The Losing Trade When "Efficiency" Becomes the Watchword in Washington2 weeks agoENERGYThe BLM Calendar That Moves COP and OXYlast weekENERGYThe Pipe Tax: How Section 232 Steel Tariffs Rewire U.S. Drilling Economicslast weekENERGYThe Permian Methane Rule: Why Stricter EPA Standards Are a HAL and SLB Giftlast weekENERGYThe Tax Code Oil Patch: Who Gets Crushed If Washington Kills the IDC Deductionlast weekDEFENSEGolden Dome Is a Sensor and Software Story Before It's a Missile Storylast weekDEFENSEThe Space-Based ISR Land Grab Nobody's Pricing In: Rocket Lab's Vertical Integration Betlast weekDEFENSEAxon Is a Homeland-Security Policy Stock Wearing a Police-Gear Disguiselast weekDEFENSEWho Actually Builds the Targets: The Overlooked Business Inside Kratoslast weekENERGYThe Permit Logjam Is Breaking: Williams and Kinder Morgan Hold the Keyslast week
That's your last free article this week. Create a free account for 2 a week — or go Pro for everything.Go Pro →
Healthcare & FDA

FDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Get a Bigger Market

Lowering the age threshold for the first CRISPR gene therapy meaningfully expands the addressable patient pool for both companies.

Image: Money Racket
By at Money Racket · Jul 5, 2026

The FDA approved a supplemental application for Casgevy (exagamglogene autotemcel) to treat sickle cell disease and transfusion-dependent beta thalassemia in patients aged 2 and older, down from the previous 12-and-older label. Casgevy is the first CRISPR-based gene therapy approved in the US.

Who cashes in: Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) co-developed and co-commercialize Casgevy, splitting economics roughly equally. Sickle cell disease disproportionately affects children, so moving the label down to age 2 is not a minor tweak — it opens the therapy to the highest-burden segment of the patient population. At a list price north of $2 million per patient, even a handful of additional annual treatments is meaningful revenue. Vertex is the larger, more diversified company; CRSP is the higher-beta pure-play on this specific catalyst. bluebird bio (BLUE) markets a competing gene therapy (Lyfgenia) for sickle cell and could see competitive pressure as Casgevy's label broadens, but bluebird's financial position is precarious enough that this is more of a watch item than a direct trade.

Sickle cell disease hits hardest in childhood. Moving Casgevy's label to age 2 opens the therapy to the patients who need it most — and expands the revenue pool for Vertex and CRISPR Therapeutics.

Who's exposed: bluebird bio (BLUE) is the most direct competitive casualty. Its Lyfgenia therapy targets the same disease, and Casgevy's expanding label — combined with its CRISPR profile — makes the competitive dynamic harder for bluebird. Hydroxyurea manufacturers and chronic transfusion programs face long-term volume pressure as curative therapies become accessible to younger patients, though that's a slow-moving dynamic.

What to watch: Payer coverage decisions for the pediatric population. Gene therapies at $2M+ per patient face real reimbursement friction, especially for children where long-term durability data is still accumulating. Watch for CMS and major commercial insurer coverage policy updates — those will determine how quickly the expanded label translates to actual revenue.

Source: original report ↗

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $40/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Go Pro · $40/mo The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Go Pro · $40/mo →